319 related articles for article (PubMed ID: 17684033)
21. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.
Alam N; Atenafu EG; Tse G; Viswabandya A; Gupta V; Kim D; Lipton JH; Messner HA; Kuruvilla J
Clin Transplant; 2013; 27(6):930-7. PubMed ID: 24304375
[TBL] [Abstract][Full Text] [Related]
22. [Anti-CD25 monoclonal antibody with antithymocytic globulin for steroid-resistant severe acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation].
Ye CX; Sun J; Liu QF; Qu H; Xu D; Zhang Y; Meng FY
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Dec; 28(12):2224-6. PubMed ID: 19114364
[TBL] [Abstract][Full Text] [Related]
23. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody.
Kobbe G; Schneider P; Rohr U; Fenk R; Neumann F; Aivado M; Dietze L; Kronenwett R; Hünerlitürkoglu A; Haas R
Bone Marrow Transplant; 2001 Jul; 28(1):47-9. PubMed ID: 11498743
[TBL] [Abstract][Full Text] [Related]
24. Alemtuzumab as salvage therapy for steroid and ATG/etanercept-refractory acute GVHD.
Jackson K; Curley C; Leach J; McLean A; Nakagaki M; Durrant S; Kennedy GA
Bone Marrow Transplant; 2011 Dec; 46(12):1579-80. PubMed ID: 21258421
[No Abstract] [Full Text] [Related]
25. Crypt loss is a marker of clinical severity of acute gastrointestinal graft-versus-host disease.
Melson J; Jakate S; Fung H; Arai S; Keshavarzian A
Am J Hematol; 2007 Oct; 82(10):881-6. PubMed ID: 17570511
[TBL] [Abstract][Full Text] [Related]
26. Acute graft-versus-host disease after liver transplant: novel use of etanercept and the role of tumor necrosis factor alpha inhibitors.
Thin L; Macquillan G; Adams L; Garas G; Seow C; Cannell P; Augustson B; Mitchell A; Delriveire L; Jeffrey G
Liver Transpl; 2009 Apr; 15(4):421-6. PubMed ID: 19326415
[TBL] [Abstract][Full Text] [Related]
27. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.
Wolff D; Wilhelm S; Hahn J; Gentilini C; Hilgendorf I; Steiner B; Kahl C; Junghanss C; Hartung G; Casper J; Uharek L; Holler E; Freund M
Bone Marrow Transplant; 2006 Sep; 38(6):445-51. PubMed ID: 16951692
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of low-dose methotrexate for pediatric patients with steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation.
Inagaki J; Fukano R; Kodama Y; Nishimura M; Shimokawa M; Okamura J
Ann Hematol; 2014 Apr; 93(4):645-51. PubMed ID: 24146233
[TBL] [Abstract][Full Text] [Related]
29. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
30. Updated experience with inolimomab as treatment for corticosteroid-refractory acute graft-versus-host disease.
García-Cadenas I; Valcárcel D; Martino R; Piñana JL; Novelli S; Esquirol A; Garrido A; Moreno ME; Granell M; Moreno C; Saavedra S; Briones J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2013 Mar; 19(3):435-9. PubMed ID: 23178634
[TBL] [Abstract][Full Text] [Related]
31. Daclizumab has poor efficacy in steroid-refractory severe acute graft-versus-host disease: a single centre experience with 12 allograft patients.
Hui CH; Sia H; Mangos H; Horvath N; Lee H; Lewis I; Hughes T; To LB; Bardy P
Bone Marrow Transplant; 2008 Feb; 41(4):409-10. PubMed ID: 18026147
[No Abstract] [Full Text] [Related]
32. Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease.
Kennedy GA; Butler J; Western R; Morton J; Durrant S; Hill GR
Bone Marrow Transplant; 2006 Jun; 37(12):1143-7. PubMed ID: 16699531
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
[TBL] [Abstract][Full Text] [Related]
34. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.
Wolff D; Roessler V; Steiner B; Wilhelm S; Weirich V; Brenmoehl J; Leithaeuser M; Hofmeister N; Junghanss C; Casper J; Hartung G; Holler E; Freund M
Bone Marrow Transplant; 2005 May; 35(10):1003-10. PubMed ID: 15806135
[TBL] [Abstract][Full Text] [Related]
35. Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease.
Pidala J; Kim J; Roman-Diaz J; Shapiro J; Nishihori T; Bookout R; Anasetti C; Kharfan-Dabaja MA
Ann Transplant; 2010; 15(4):21-9. PubMed ID: 21183872
[TBL] [Abstract][Full Text] [Related]
36. Acute graft-versus-host disease in children.
Jacobsohn DA
Bone Marrow Transplant; 2008 Jan; 41(2):215-21. PubMed ID: 17934526
[TBL] [Abstract][Full Text] [Related]
37. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
[TBL] [Abstract][Full Text] [Related]
38. Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation.
Yang J; Cheuk DK; Ha SY; Chiang AK; Lee TL; Ho MH; Chan GC
Pediatr Transplant; 2012 Nov; 16(7):771-8. PubMed ID: 22905718
[TBL] [Abstract][Full Text] [Related]
39. An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease.
Margolis J; Vogelsang G
Semin Oncol; 2000 Apr; 27(2 Suppl 5):72-7. PubMed ID: 10877057
[TBL] [Abstract][Full Text] [Related]
40. Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-
Shen MZ; Li JX; Zhang XH; Xu LP; Wang Y; Liu KY; Huang XJ; Hong SD; Mo XD
Front Immunol; 2021; 12():749266. PubMed ID: 34621279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
